Samsara BioCapital, L.P. insider trades: Kalaris Therapeutics (KLRS) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Samsara BioCapital, L.P. reports to the SEC
and 1 more company
Open-market buys and sales
16 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 18, 2025 | KLRS | ↑ Buy | 479,847 | $10.42 | $5.0M | By Samsara Opportunity Fund, L.P. | Feb 17, 2026 (61d) |
| Mar 13, 2025 | MLYS | ↑ Buy | 600,000 | $13.50 | $8.1M | By Samsara BioCapital, L.P. | Mar 17, 2025 (4d) |
| Nov 26, 2024 | NGNE | ↑ Buy | 48,770 | $25.83 | $1.3M | By Samsara BioCapital, L.P. | Nov 27, 2024 (1d) |
| May 30, 2024 | CRGX | ↑ Buy | 294,000 | $17.00 | $5.0M | By Samsara BioCapital, L.P. | Jun 3, 2024 (4d) |
| Feb 12, 2024 | MLYS | ↑ Buy | 555,555 | $13.50 | $7.5M | Indirect | Feb 14, 2024 (2d) |
| Nov 14, 2023 | CRGX | ↑ Buy | 666,666 | $15.00 | $10.0M | By Samsara BioCapital, L.P. | Nov 16, 2023 (2d) |
| Oct 16, 2023 | SRRK | ↑ Buy | 2,189,781 | $6.85 | $15.0M | By Samsara BioCapital, L.P. | Oct 18, 2023 (2d) |
| Feb 14, 2023 | MLYS | ↑ Buy | 937,500 | $16.00 | $15.0M | Indirect | Feb 16, 2023 (2d) |
| Apr 12, 2022 | GRPH | ↑ Buy | 424,464 | $4.08 | $1.7M | By Samsara BioCapital, L.P. | Apr 13, 2022 (1d) |
| Jan 24, 2022 | GRPH | ↑ Buy | 123,000 | $8.94 | $1.1M | By Fund | Jan 25, 2022 (1d) |
| Jan 20, 2022 | GRPH | ↑ Buy | 97,670 | $9.10 | $889K | By Fund | Jan 21, 2022 (1d) |
| Dec 15, 2021 | GRPH | ↑ Buy | 22,329 | $10.19 | $228K | By Fund | Dec 20, 2021 (5d) |
| Nov 22, 2021 | GRPH | ↑ Buy | 201,685 | $10.15 | $2.0M | By Fund | Nov 24, 2021 (2d) |
| Oct 15, 2021 | GRPH | ↑ Buy | 50,800 | $13.14 | $668K | By Fund | Oct 15, 2021 (0d) |
| Oct 8, 2021 | GRPH | ↑ Buy | 145,496 | $13.53 | $2.0M | By Fund | Oct 8, 2021 (0d) |
| Jun 29, 2021 | GRPH | ↑ Buy | 500,000 | $17.00 | $8.5M | By Fund | Jul 1, 2021 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other KLRS insiders
Open-market trades in the last 12 months
About Samsara BioCapital, L.P.'s insider trades
Samsara BioCapital, L.P. is a 10% owner of Kalaris Therapeutics (KLRS). Since Jun 29, 2021, it has reported 16 open-market purchases worth $84.0M and no sales on SEC Form 4. In the last 12 months: 1 buy ($5.0M).
Its filings also include grants and awards (4 filings), conversions (3 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every KLRS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.